Stock Price Quote

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE502.001.85 (+0.37 %)
PREV CLOSE ( ) 500.15
OPEN PRICE ( ) 500.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10772
TODAY'S LOW / HIGH ( )492.90 512.50
52 WK LOW / HIGH ( )273.7 543
NSE501.851.9 (+0.38 %)
PREV CLOSE( ) 499.95
OPEN PRICE ( ) 499.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 66877
TODAY'S LOW / HIGH( ) 492.20 513.30
52 WK LOW / HIGH ( )275.05 543.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 20-01 1995
Management Info
Kishor M Shah - Chairman Mahendra G Patel - Managing Director
Registered Office

Address Lincoln House", Behind Satyam Complex,Science City Road,Sola,
Ahmedabad,
Gujarat-380060

Phone 079-41078000

Email investor@lincolnpharma.com

Website www.lincolnpharma.com

Registrars Details
Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE, Ahmedabad

NEWS

26Aug Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that it enclosed copies of publishe..
11Aug Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that it enclosed e-copies of newspa..
26May Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that it enclosed copies of publishe..
25May Lincoln Pharmaceuticals informs about
Further to letter dated May 15, 2023 and pursuant to Regulation 30 and 3..
12May Lincoln Pharmaceuticals informs about
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit190.13728.99
Gross Profit 254.46 1004.55
Operating Profit 284.061116.5
Net Sales 1356.195103.09

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  5671.65 (1.08%)
M.Cap ( in Cr)94594.48
Mankind Pharma (BSE)
peergroup  1740.15 (1.87%)
M.Cap ( in Cr)69708.40
TTK Healthcare (BSE)
peergroup  1175.95 (1.79%)
M.Cap ( in Cr)1661.66
Ajanta Pharma (BSE)
peergroup  1720.55 (1.15%)
M.Cap ( in Cr)21664.42
RPG Life Sciences (BSE)
peergroup  1333.50 (1.40%)
M.Cap ( in Cr)2205.48

Shareholding Pattern

NON-INSTITUTION 49.58%
PROMOTERS 48.67%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Lincoln Pharmaceuticals Ltd.

Lincoln Pharmaceuticals Ltd. was incorporated in the year 1995. Its today's share price is 502. Its current market capitalisation stands at Rs 1005.49 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4965.31 Cr and Total Income of Rs.4820.77 Cr. The company's management includes Trusha Shah, Saurin J Parikh, Meha Patel, Pirabhai Suthar, Rajnikant G Patel, Munjal M Patel, H I Patel, Ashish Patel, Mahendra G Patel, Kishor M Shah.

It is listed on the BSE with a BSE Code of 531633 , NSE with an NSE Symbol of LINCOLN and ISIN of INE405C01035. It's Registered office is at Lincoln House", Behind Satyam Complex,Science City Road,SolaAhmedabad-380060, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Chandulal M Shah & Co, DK Chhajer & Co, JT Shah & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.